WO1994006821A1 - A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use - Google Patents
A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use Download PDFInfo
- Publication number
- WO1994006821A1 WO1994006821A1 PCT/NL1992/000160 NL9200160W WO9406821A1 WO 1994006821 A1 WO1994006821 A1 WO 1994006821A1 NL 9200160 W NL9200160 W NL 9200160W WO 9406821 A1 WO9406821 A1 WO 9406821A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- proteins
- allergenic
- compounds
- extracts
- pollen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the present process relates to a process for the purification of aqueous extracts containing allergenically active proteins and further containing non-allergenic undesirable compounds.
- the causative major allergenic components in extracts of pollen are proteins iri the molecular weight range of 20 - 70 kD, whereas the constituents below the 10 kD molecular weight range are believed to be non-allergenic, it has become common practice in the manufacturing process of pollen extracts for diagnosis and immunotherapy to dialyse or ultrafilter the aqueous pollen extracts through membranes of 5-10 kD nominal cut-off in order to remove supposedly irrelevant components with a molecular size lower than 5 ⁇ 10 kD, thereby retaining the allergenic proteins in the molecular size range of 10-100 kD in order to improve the quality of the allergenic extract for clinical application.
- the present invention provides a process for the purification of aqueous extracts containing allergenically active proteins and further containing non-allergenic undesirable compounds, which process yields highly purified extracts containing substantially allergenically active proteins, which extracts do not suffer from the (not always recognized) disadvantages of the conventional aqueous extracts containing allergenically active proteins.
- the present invention relates to a process for the purification of aqueous extracts containing aller ⁇ genically active proteins and further containing non-allergenic undesirable compounds, wherein said non-allergenic compounds adhering to said proteins are removed from said proteins by using means which disrupt electrostatic forces and/or hydrophobic forces being responsible for the adherence of said non-allergenic compounds to said proteins.
- the process according to the invention com ⁇ prises the following steps: 1) providing an aqueous extract containing allergenically active protein(s) and further containing non-allergenic undesirable compounds as a starting material. 2) subjecting said starting material to a treatment to remove said non-allergenic compounds, which adhere to said proteins, from said proteins in which means are used which disrupt electrostatic forces and/or hydrophobic forces being respon- sible for the adherence of said non-allergenic compounds to said proteins, to obtain an aqueous extract substantially free from said adhering undesirable compounds,
- impurities such as flavonoids and/or glycosides, but also other compounds, exemplified in the below, are contained in the usual extracts, but not in a "free” form.
- the "adherence" of the impurities to the allergenically active proteins may be based on Van der aals forces, ionic bonding, hydrophobic interaction or even chemical interaction (covalent forces).
- the means for disrupting electrostatic or other physical forces are selected from the group of chemical means consisting of acid, and alkaline materials including anion- and cation-exchanging materials, salts and electric currents.
- a pH-value of e.g. 9-H i.e. above the usual electric points, may be used.
- the acid and alkali concentrations may be in the order of 0.1 N to 0.01 N for (strong) acids and 0.01-0.001 N for (strong) alkali.
- the absolute salt concentration or ionic strength is relevant.
- monovalent salts are used, e.g. NaCl, KC1, KCNS, the corresponding bromides, or e.g. guanidine-HCl.
- the value of the ionic strengths is between 2-6 M, preferably 2-5 M. It should be noted that higher concentrations, e.g. of guanidine-HCl, tend to disrupt hydrogen bonds of the carrier protein as well as inter-chain linkages of composite proteins.
- the means for disrupting electrostatic forces and physical forces comprise electric currents in the form of electrophoresis.
- the electrophoresis is carried out with the aqueous extracts.
- electrophoresis should not be performed too long in order to avoid local heat exposure or (complete) denaturation of the protein.
- a reasonably high electrical potential across the applied electrodes should be used, e.g. in general between 10-2000 Volts DC, in particular between 200-1000 Volts DC. If the potential is too high, the protein carriers themselves may suffer some pertub- ation of their colloid-chemical zeta potential, thereby irreversibly causing unfolding of the tertiary or even secondary structure and a loss of the stabilizing water layer.
- the electrical cur ⁇ rent is dependent on the salt concentration in the solution, normally a buffer solution.
- flavonoids and/or glycosides are removed.
- Flavonoids - occurring in the present aqueous extracts - affect arachidonic acid metabolism and interact as phenols or quinoid derivatives with macromolecules, causing for example enzyme inactivation due to complex formation with tannin-like polymers. Strong interaction with proteins is in fact a general property of polyphenols (among them the flavonoids), their oxidation products and their polymers.
- the interaction of the impurities being present in the extracts used as starting materials in the process of the invention can be physical (Van der Waals forces, ionic bonding, hydrophobic interactions) or chemical (covalent forces by interaction with oxidized (bi-)phenols.
- Flavonoids and flavonoidglycosides as individual molecules inhibit histamine release from mast cells and basophils and modulate to a considerable degree the normal functions of polymorphonuclear leuco ⁇ cytes and neutrophils. These biological activities may have considerable impact on the outcome of diagnostic skin and inhalation tests with prior art preparations routinely performed in allergic patients.
- it has already been extensively docu- mented in European Patent Application No. 90200562.8 that low-mol ⁇ ecular weight (M ⁇ 5000) water-soluble and non-adsorbed flavonoid ⁇ glycosides do not contribute to the binding of IgE antibodies in the serum of specifically sensitized allergic patients.
- the removal of impurities such as flavonoids and their glycosides from the customary diagnostic and therapeutic pollen protein vaccines may therefore improve their usefulness and efficacy in clinical medi ⁇ cine.
- a further argument for eliminating adsorbed low-molecular compounds from plant pollen proteins administered to man is that many pollen species, like the plants elaborating them, may contain low-mass (M ⁇ 1000) non-flavonoid organic compounds potentially harmful to man, e.g. toxic alkaloids, benzochinones, terpenoids and their derivatives irritating to mucous membranes, and other aromatic structures. Like the flavonoids, such components may in some instances resist simple dialysis or ultrafiltration at neutral pH through membranes of 10 kD nominal cut-off by remaining firmly adsorbed to proteins by physical forces.
- the invention also relates to extracts obtainable according to the processes of the invention as described herein.
- Such purified extracts ensure the safety of allergenic plant pollen extracts intended for the diagnosis and treatment of allergic diseases.
- a broad variety of extracts of naturally occurring materials may be (further) purified. Representative examples are:
- Grass and Weed Pollens Hordeu vulga e, Agrostis tenuis, Poa annua, Poa compressa, Poa pratensis, Poa sandbergii, Bromus rigidus, Bromus carinatus, Bromus secalinus, Bromus inermis, Bromus mollis, Agropyron spicatum, Phalaris canariensis, Phalaris arundinacea, Festuca rubra, Bouteloua graci lis, Koele ⁇ ia cristata, Eragrostis va ⁇ iabilis, Avena sativa, Avena elatior (Arrhenatherum elatius), Agropyron repens, Agrostis alba, Secale cereale, Elymus triticoides, Elymus cinereus, Lolium multiflorum, Elymus glaucus, Distichlis stricta, Sorghum vulgare, Sorghum vul
- Camel Hair & Dander Cattle Hair & Dander; Cat Hair and Dander; Deer Hair & Dander; Feathers, Chicken; Feathers, Duck; Feathers, goose; Feathers, Parakeet; Feathers, Pigeon; Feathers, Turkey; Fox Fur; Gerbil Hair & Epithelium; Goat Hair __ Dander; Guina Pig Hair & Dander; Hamster Hair & Epithelium; Hog Hair & Dander; Horse Hair & Dander; Human Dander; Monkey Hair & Epithelium; Mouse Hair & Epithelium; Dog Breeds Hair & Dander; Pyrethrum; Rabbit Hair & Epithelium; Rat Hair & Epithelium;
- Ant (Black and Red); Ants, Carpenter; Ants, Fire; Blakfly; Butter ⁇ fly; Caddis Fly; Cricket; Cockroach; Deer Fly; Flea antigen;. Fruit Flies; Gnat sp.; House Fly; Mayfly sp.; Mite (D. farinae, D. pteronyssimus , Lepidaglyphus spp.); Moth.
- the present invention also relates to the use of the purified extracts obtainable according to the invention, for standardization, diagnosis, synthesis, and vaccination purposes. Specific embodiments of the present invention are illustrated by the following procedures A-C. Procedure A
- Pollen granules are collected from botanically identified plants and dried in air at ambient temperature. Lipids, fatty acids, free flavonoids and other apolar free organic substances are then removed from the dry pollen by continuous extraction in a Soxhlet apparatus with organic solvents non-miscible with water, e.g. dry diethylether or n-hexane. The defatted pollen mass is again dried in air and subsequently extracted for 2 hours under mechanical agitation at a temperature between 4-20°C with aqueous solvents, i.e. dilute buffer or ammonium bicarbonate solutions, or with distilled water at a pH-value maintained between 6-8.5. The mixture is then centrifuged for 30 minutes at about 3000-5000 r.p.m.
- aqueous solvents i.e. dilute buffer or ammonium bicarbonate solutions
- the (combined) aqueous extract(s) is clarified by filtration through ordinary filter paper and then dialysed for 18 h against several changes of distilled water with a pH-value no lower than 5-5-6.0 and no higher than pH 7-5.
- the dialysis step use is made of commercial membranes with a nominal cut-off of 5-10 kD (e.g. Visking cellophane dialysis tubing) or, alternatively, the extract may be diafiltered through suitable membranes of the same cut-off range (e.g. Amicon or Millipore Ultra- or DiaFilter Membranes).
- the non- dialysable retentate solution, containing the high molecular (HMW) allergenic proteins is finally taken to dryness by lyophilisation, or processed directly from solution for further purification of the allergenic proteins of M>5 ⁇ 10 kD.
- the lyophilised material HMW is redissolved in distilled water to a concentration of 0.5-1-0 % w/v and the pH of the solution is adjusted to pH 2 by the dropwise addition of 6 N( or more concentrated) HC1.
- the extract is then re- dialysed for 24 h at a temperature between 4-20"C against 100 volumes of distilled water (pH 6-7-5) as the outer liquid.
- the outer liquid is kept under constant agitation by placing the vessel holding both the outer liquid and the free- floating dialysis bags on a magnetic stirrer.
- the pH-value of the outer fluid has risen to about pH 3-5- It was found that the use of acidified water at pH 2 as the outer liquid directly at the start of the process does not improve the efficiency of the release of adsorbed pigments.
- the retentate fluid inside the dialysis bag or retained by the diafilter membrane is brought to pH 6.5-7-5 under stirring by the dropwise addition of 1 N NaOH.
- the thus neutralized solution is finally dried by lyophili ⁇ sation to recover the depigmented allergenic pollen proteins DPP as end product.
- Example III it was shown in the present procedure that the lowering of the pH by itself does not seriously impede the antibody recognition sites of the allergenic proteins.
- the procedure outlined above removes 15-65 % w/w of adsorbed pigments relative the dry weight of the orginal allergenic pollen protein preparation HMW (table I).
- the desorbed pigment material which in some cases also contains small peptides, may be recovered separately by concentrating the neutralised outer liquid under reduced pressure in a rotating thin-film evaporating apparatus.
- the process is controlled by ultraviolet absorption spectroscopy.
- the extinction values at 260-280 nm of aqueous solutions of classical pollen proteins HMW, pre- dialysed at neutral pH but before acid desorption and re-dialysis may achieve very high values, especially with the non-depigmented allergenic proteins of the pollens of the trees, weeds and shrubs.
- Estimates of the protein content from the extinction coefficients at 260-280 nm in many cases therefore leads to overestimates.
- the removal of adsorbed pigments causes a significant drop in the extinction coefficients in the 260-280 nm range as well as at 340-360 nm, the major absorption range of the flavonols (Table II).
- Table II Changes in UV-extinction coefficients E ( 1% , 1 cm) at pH2 (HC1) before and after depigmentation by acid dialysis.
- the allergenic potency of the final depigmented product DPP is compared with that of the original pollen proteins HMW by inhibition of the binding of specific IgE- or IgG-class antibodies in the blood serum of specifically allergic pollinosis patients.
- the IgE-binding potency of the DPP product relative to the HMW preparation may for example be quantitatively determined by the chemical coupling of either the HMW or the DPP product to cellulose discs with cyanogen bromide or other coupling agents, followed by IgE antibody assay according to the established procedures of radioallergosorbent- or enzyme-allergosorbent tests.
- either the DPP or the HMW proteins may be adsorbed physically to the surface of the wells of polystyrene microtiter plates, followed by established procedures of enzyme immunoassay.
- B of the invention demonstrates that the firm adsorption of flavonoid- or flavonoid-glycoside pigments to pollen proteins is largely due to electrostatic forces, which can be overcome for purposes of desorption by discharging negative carboxyl- and/or phenolic hydroxyl groups of either partner at a pH-value below 3-0.
- electrostatic forces which can be overcome for purposes of desorption by discharging negative carboxyl- and/or phenolic hydroxyl groups of either partner at a pH-value below 3-0.
- a procedure was developed based on the elimination of adsorbed pigments in an electric field in the neutral pH-range of 6.5-7-5-
- a 2-5 % solution is made of the lyophilised allergenic proteins HMW described in Procedure A, in a 0.01 M in ⁇ organic buffer salt solution pH 6.5 ⁇ 7-5 t for example a phosphate- buffered saline solution.
- a suitable volume of this solution is then subjected to free electrophoresis to disrupt the ionic forces causing protein- pigment adsorption. During the electrophoresis the pigments rapidly move to the cathode compartment and may thus be separated from the slow-moving protein constituents, which remain on the anodic side.
- a technical prototype of this Procedure is given in Example IV.
- Ambrosia elatior obtained commercially from Beecham Research Laboratories, England
- a sample of 25 mg was dissolved in ml distilled water and the solution was brought to pH 2 by the dropwise addition of 6 N HCl.
- the ultraviolet absorption spectrum was separately observed at 1:20 dilution in 0.01 N HCl.
- the sample was dialysed under stirring and at ambient temperature for 24 hours against a total volume of 500 ml of distilled water.
- Example II the same procedure as described in Example I was followed with the pollen of Lolium perenne and Dactylis glomerata as representative examples of potent allergenic pollens of the botanical family of the Gramineae, and of Chenopodium album and Artemisia vulgaris as well-known representatives of allergenic pollens of weeds.
- the numerical data with respect to yields of DPP from HMW as well as the pertinent spectroscopic figures are listed in Tables I and II.
- a serum sample of a patient with pollinosis due to the pollen proteins to be investigated is incubated with a cellulose disc to which either the pollen proteins HMW or the depigmented counterparts DPP have been covalently bound with the aid of cyanogen bromide or another suitable chemical coupling agent.
- the discs are washed in a dilute buffer solution, followed by an incubation step with an enzyme-labelled anti-IgE-antibody, and the colour is finally developed with an enzyme-specific chromogenic substrate.
- the IgE-binding potency of a given allergenic protein For the evaluation of the IgE-binding potency of a given allergenic protein, sequential dilutions of the allergen are preincubated with a fixed volume of the human serum sample before the capture of residual IgE by the allergen-coated cellulose disc.
- the IgE-binding potency of the allergenic preparation is read as the point of 50 % inhibition from a plot of allergen concentration versus IgE-binding, as shown for the example of Betula alba pollen in Figure 3- In the present Example use was made of two kinds of allergen-coated cellulose discs, viz.
- the decrease of IgE- binding allergenicity of Olea pollen DPP relative to Olea HMW is not due to protein denaturation at acid pH, but to removable pigments or other electrostatically adsorbed low-molecular weight organic compounds acting as true antigenic determinants.
- Comparative studies along these lines underline the usefulness of depigmented pollen proteins for in-depth studies of the molecular structure of anti ⁇ body-binding allergenic epitopes. For the inhibition of binding to specific IgG antibodies an established method of enzyme im unoassay was chosen.
- a serum sample of a patient with pollinosis due to the pollen proteins to be investigated is incubated with sequential dilutions of the HMW or DPP allergen.
- the allergen-serum mixtures are then pipetted into the wells of polystyrene microtiter plates pre-coated with either the HMW or DPP proteins by physical adsorption. After 30 minutes at room temperature, the wells are then washed with dilute buffer solution and the specific IgG antibody captured on the allergen-coated plate is determined by treatment with an enzyme- labelled anti IgG-antiserum, followed by colour development with an enzyme-specific chromogenic substrate.
- the IgG-binding potency of the allergen preparation is evaluated as the point of 50 % inhibition interpolated on the plot of allergen concentration versus IgG-binding.
- the microtiter wells were in all cases coated with the DPP-preparations produced according to procedure A.
- the data in Table III show that the potency of the DPP in IgG-binding increases slightly relative to the HMW products.
- Figures given represent ⁇ g of preparation required for 50 % of antibody binding in the test system chosen.
- Electrophoresis was then started by applying a DC electric potential at a constant power of 12 Watts under continuous rotation of the tube holding the dialysis bag and the outer liquid. The current drupped from 120 mA at the start of the experiment to 68 mA after 3 hours.
- the pigments are released from the pollen proteins and migrate out of the dialysis bag to the cathodic com ⁇ partment of the outer liquid (negative pole) .
- the depigmented proteins were recovered from the solution inside the dialysis bag and dried by lyophilization.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE122005000035C DE122005000035I2 (en) | 1992-09-21 | 1992-09-21 | PROCESS FOR CLEANING WAESSER EXTRACTS CONTAINING ALLERGENIC PROTEINS, EXTRACTS OBTAINED THEREOF, AND THEIR USE |
EP92920684A EP0662080B1 (en) | 1992-09-21 | 1992-09-21 | A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use |
AU26486/92A AU675629B2 (en) | 1992-09-21 | 1992-09-21 | A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use |
DE69217395T DE69217395T2 (en) | 1992-09-21 | 1992-09-21 | METHOD FOR PURIFYING AQUEOUS EXTRACTS CONTAINING ALLERGENIC PROTEINS, EXTRACTS SO OBTAINED, AND THEIR USE |
CA002145169A CA2145169C (en) | 1992-09-21 | 1992-09-21 | A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use |
ES92920684T ES2098543T3 (en) | 1992-09-21 | 1992-09-21 | A PROCESS FOR THE PURIFICATION OF AQUEOUS EXTRACTS CONTAINING ALLERGENICALLY ACTIVE PROTEINS, EXTRACTS OBTAINABLE ACCORDING TO THIS PROCESS, AS WELL AS THEIR USE. |
AT92920684T ATE148708T1 (en) | 1992-09-21 | 1992-09-21 | METHOD FOR PURIFYING AQUEOUS EXTRACTS CONTAINING ALLERGENIC PROTEINS, EXTRACTS SO OBTAINED AND THEIR USE |
PCT/NL1992/000160 WO1994006821A1 (en) | 1992-09-21 | 1992-09-21 | A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use |
US08/403,832 US5770698A (en) | 1992-09-21 | 1992-09-21 | Process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use |
JP50798394A JP3397791B2 (en) | 1992-09-21 | 1992-09-21 | Purification method of aqueous extract containing protein active as allergen, extract obtained by this method and use thereof |
DE200512000034 DE122005000034I1 (en) | 1992-09-21 | 1992-09-21 | Process for the purification of aqueous extracts containing allergenic proteins, extracts thus obtained and their use. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002145169A CA2145169C (en) | 1992-09-21 | 1992-09-21 | A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use |
PCT/NL1992/000160 WO1994006821A1 (en) | 1992-09-21 | 1992-09-21 | A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994006821A1 true WO1994006821A1 (en) | 1994-03-31 |
Family
ID=25677852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL1992/000160 WO1994006821A1 (en) | 1992-09-21 | 1992-09-21 | A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP3397791B2 (en) |
CA (1) | CA2145169C (en) |
WO (1) | WO1994006821A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999022762A1 (en) | 1997-10-30 | 1999-05-14 | C.B.F. Leti, S.A. | Tolerogenic fragments of natural allergens |
EP1637147A1 (en) * | 2004-09-18 | 2006-03-22 | Bufe, Albrecht, Prof. Dr. med. | Stable dust extract for allergy protection |
EP1834649A1 (en) * | 2006-03-14 | 2007-09-19 | Alk-Abello A/S | Method of developing a process for producing an allergen extract |
EP1834648A1 (en) * | 2006-03-14 | 2007-09-19 | Alk-Abello A/S | Process for producing an allergen extract |
US7887821B2 (en) | 2007-12-20 | 2011-02-15 | Alk-Abello A/S | Process for producing an allergen extract |
WO2011098569A1 (en) * | 2010-02-12 | 2011-08-18 | Laboratorios Leti, S.L. Unipersonal | Process for producing an allergen extract |
WO2020186624A1 (en) * | 2018-03-23 | 2020-09-24 | 中国医学科学院北京协和医院 | Humulus pollen allergen extract and infusion, and a preparation method therefor |
CN113825518A (en) * | 2019-01-17 | 2021-12-21 | 莱蒂生物制药公司 | Method for purifying allergen extract |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1872792A1 (en) * | 2006-06-29 | 2008-01-02 | Biotech Tools S.A. | A method for the production of hydrolyzed allergen |
-
1992
- 1992-09-21 WO PCT/NL1992/000160 patent/WO1994006821A1/en active IP Right Grant
- 1992-09-21 JP JP50798394A patent/JP3397791B2/en not_active Expired - Lifetime
- 1992-09-21 CA CA002145169A patent/CA2145169C/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
BIOLOGICAL ABSTRACTS vol. 75 , 1983, Philadelphia, PA, US; abstract no. 85052, GUERIN, B. ET AL. 'RADIOALLERGOSORBENT TEST INHIBITION, 2-DIMENSIONAL IMMUNOELECTROPHORESIS AND ANALYTICAL ISOELECTRIC FOCUSING IN THE IDENTIFICATION OF CONTAMINATION IN GRASS POLLEN EXTRACTS' * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999022762A1 (en) | 1997-10-30 | 1999-05-14 | C.B.F. Leti, S.A. | Tolerogenic fragments of natural allergens |
AU729589B2 (en) * | 1997-10-30 | 2001-02-08 | C.B.F. Leti, S.A. | Tolerogenic fragments of natural allergens |
AU729589C (en) * | 1997-10-30 | 2001-08-30 | C.B.F. Leti, S.A. | Tolerogenic fragments of natural allergens |
US6350590B1 (en) | 1997-10-30 | 2002-02-26 | C.B.F. Leti, S.A. | Tolerogenic fragments of natural allergens |
US6660495B2 (en) | 1997-10-30 | 2003-12-09 | C.B.F. Leti, S.A. | Tolerogenic fragments of natural allergens |
EP2042192A3 (en) * | 1997-10-30 | 2009-05-27 | Laboratorios LETI, S.L. | Tolerogenic fragments of natural allergens |
CZ302352B6 (en) * | 1997-10-30 | 2011-03-30 | C. B. F. Leti, S. A. | Process for preparing extracts providing tolerance against allergenic material and their use |
EP1637147A1 (en) * | 2004-09-18 | 2006-03-22 | Bufe, Albrecht, Prof. Dr. med. | Stable dust extract for allergy protection |
WO2006029685A1 (en) * | 2004-09-18 | 2006-03-23 | Albrecht Bufe | Barn dust extract providing protection from allergies |
EP1834649A1 (en) * | 2006-03-14 | 2007-09-19 | Alk-Abello A/S | Method of developing a process for producing an allergen extract |
EP1834648A1 (en) * | 2006-03-14 | 2007-09-19 | Alk-Abello A/S | Process for producing an allergen extract |
US7887821B2 (en) | 2007-12-20 | 2011-02-15 | Alk-Abello A/S | Process for producing an allergen extract |
WO2011098569A1 (en) * | 2010-02-12 | 2011-08-18 | Laboratorios Leti, S.L. Unipersonal | Process for producing an allergen extract |
CN102821785A (en) * | 2010-02-12 | 2012-12-12 | 过敏症研究实验室有限公司 | Process for producing an allergen extract |
CN102821785B (en) * | 2010-02-12 | 2014-12-10 | 过敏症研究实验室有限公司 | Process for producing an allergen extract |
CN104371016A (en) * | 2010-02-12 | 2015-02-25 | 过敏症研究实验室有限公司 | Process for producing an allergen extract |
EP2853271A1 (en) * | 2010-02-12 | 2015-04-01 | Laboratorios LETI, S.L. | Allergen extracts |
AU2011214316B2 (en) * | 2010-02-12 | 2015-07-02 | Laboratorios Leti, S.L. | Process for producing an allergen extract |
RU2572230C2 (en) * | 2010-02-12 | 2015-12-27 | Лабораториос Лети, С.Л. | Method of obtaining allergen extract |
US9884111B2 (en) | 2010-02-12 | 2018-02-06 | Laboratorios Leti, S.L. | Process for producing an allergen extract |
CN104371016B (en) * | 2010-02-12 | 2018-05-15 | 过敏症研究实验室有限公司 | Allergen extract |
RU2706685C2 (en) * | 2010-02-12 | 2019-11-20 | Лабораториос Лети, С.Л. | Method of producing allergen extract |
US11246923B2 (en) | 2010-02-12 | 2022-02-15 | Laboratorios Leti, S.L. Unipersonal | Process for producing an allergen extract |
WO2020186624A1 (en) * | 2018-03-23 | 2020-09-24 | 中国医学科学院北京协和医院 | Humulus pollen allergen extract and infusion, and a preparation method therefor |
CN113825518A (en) * | 2019-01-17 | 2021-12-21 | 莱蒂生物制药公司 | Method for purifying allergen extract |
Also Published As
Publication number | Publication date |
---|---|
CA2145169A1 (en) | 1994-03-31 |
JP3397791B2 (en) | 2003-04-21 |
JPH08504187A (en) | 1996-05-07 |
CA2145169C (en) | 2003-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5770698A (en) | Process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use | |
US4963356A (en) | Stable antigenic extracts methods | |
JP6646480B2 (en) | Method for producing allergen extract | |
WO1994006821A1 (en) | A process for the purification of aqueous extracts containing allergenically active proteins, extracts obtainable according to this process as well as their use | |
Edlmayr et al. | Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases | |
Pham et al. | Cypress pollen allergy. Identification of allergens and crossreactivity between divergent species | |
US4226853A (en) | Formalinized allergen-containing substances and production thereof | |
US11617789B2 (en) | Process for the preparation of allergenic extracts | |
US5384395A (en) | Method for the isolation of primary-toxic compounds or allergens from plant material | |
KR100549557B1 (en) | Allergen formulation | |
Berrens et al. | Complement inactivation by allergenic plant pollen extracts | |
RU2809823C2 (en) | Methods of cleaning allergen extract | |
US20220110983A1 (en) | Methods of purifying an allergen extract | |
EP0083497A2 (en) | Process for preparing modified allergens, their use in treating allergic conditions | |
Freed et al. | Non‐allergenic haemolysins in grass pollens and housedust mites | |
Berrens et al. | Haemolytic complement consumption by Parietaria pollen extracts in relation to peptide-bound flavonoids | |
Berrens et al. | Complement activating agents in allergenic extracts | |
JP3124337B2 (en) | Refined mite allergen | |
CA2148007A1 (en) | Allergenic extracts | |
JPH06192299A (en) | Purified mite allergen | |
EP1235591A1 (en) | Vaccine adjuvants comprising ginseng plant extract and added aluminium salt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2145169 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992920684 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992920684 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08403832 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992920684 Country of ref document: EP |